Oral Arguments Date Set In Cases Over FDA’s Removal Of GLP-1 Drugs From Shortage List

( February 19, 2026, 8:52 AM EST) -- NEW ORLEANS — The Fifth Circuit U.S. Court of Appeals has tentatively scheduled oral arguments for March 30 in related disputes on whether a lower court erred in granting summary judgment to the U.S. Food and Drug Administration after it was sued over the removal of tirzepatide XE "tirzepatide"  and semaglutide XE "semaglutide" , FDA-approved drugs for diabetes and weight loss, from the agency’s drug shortage list....

Attached Documents

Related Sections